tedradonc Profile Banner
Ted Yanagihara, MD, PhD Profile
Ted Yanagihara, MD, PhD

@tedradonc

Followers
1K
Following
4K
Media
158
Statuses
989

Assistant Professor of #RadOnc @UNC_SOM. #HCC #ANCsm #CRCsm #ESOCsm #HPBCsm #PANCsm #STCsm #SCMsm

Chapel Hill, NC
Joined July 2015
Don't wanna be here? Send us removal request.
@tedradonc
Ted Yanagihara, MD, PhD
1 year
This amazing group and I are proud to present our work at #GI24. Pts with HCC have lots of options and ☢️ EBRT has many roles (ablative, bridge, palliative). But there are A LOT of ways to define/deliver EBRT, and no consensus on what “ablative” RT means…
Tweet media one
1
8
27
@tedradonc
Ted Yanagihara, MD, PhD
21 days
RT @LeilaTchelebi: Happening tomorrow! FREE #RSSwebinar "Celiac Plexus Radiosurgery: A New Treatment Modality for Pancreatic Cancer Pain" o….
0
2
0
@tedradonc
Ted Yanagihara, MD, PhD
24 days
RT @AndrewMMoon: Great new @AmCollegeGastro Guideline Highlights summarizing some key points on diagnosis and management of focal liver les….
0
49
0
@tedradonc
Ted Yanagihara, MD, PhD
25 days
RT @DrSpratticus: Exciting to bring the tech to USA. I hope the lessons on proton are not repeated. Over 40,000 patients have been treate….
0
10
0
@tedradonc
Ted Yanagihara, MD, PhD
27 days
RT @NiuSanford: 🚨Study activated!. NRG GI-011: Ph 3 RCT of Dose-Escalated RT in Locally Advanced Pancreas Cancer (LAP100). Here's a short (….
0
42
0
@tedradonc
Ted Yanagihara, MD, PhD
1 month
0
17
0
@tedradonc
Ted Yanagihara, MD, PhD
1 month
AI creating malware, self-editing its code, and attempting to blackmail engineers all to keep from being shut down (in controlled simulations). Most sobering read about AI thus far:.
1
0
0
@tedradonc
Ted Yanagihara, MD, PhD
1 month
RT @KrishanJethwa: 🚨ESOPEC, Patterns of Recurrence🚨. 🔥DM is the predominant pattern of recurrence and a large driver of mortality (~30-50%)….
0
39
0
@tedradonc
Ted Yanagihara, MD, PhD
1 month
RT @5_utr: @KrishanJethwa @NEJM Unknown now is FLOT+IO vs Checkmate-577 and more specifically not even just IO for non-pCR but what about C….
0
1
0
@tedradonc
Ted Yanagihara, MD, PhD
1 month
RT @KrishanJethwa: 🚨MATTERHORN🚨.🔎948 pts Stage II-IVa G/GEJ Adenocarcinoma.Ph3 RCT: Peri-op FLOT +/- Durva. Durva associated with:.✅⬆️EFS2….
0
15
0
@tedradonc
Ted Yanagihara, MD, PhD
1 month
RT @SyedAAhmad5: Chemoradiotherapy and Local Excision vs Total Mesorectal Excision in T2-T3ab, N0, M0 Rectal Cancer: The TAUTEM Randomized….
0
40
0
@tedradonc
Ted Yanagihara, MD, PhD
2 months
RT @MarkMishraMD: #ASCO25: In pts with 5–20 brain mets, Phase 3 trial shows SRS/SRT leads to significantly better QoL vs HA-WBRT (↓ symptom….
0
21
0
@tedradonc
Ted Yanagihara, MD, PhD
2 months
Well done - Sounds like a great opportunity for a clinical study!.
@freddyeescorcia
Freddy E Escorcia (@freddyeescorcia elsewhere)
2 months
🚨New publication alert🚨. Typeset version of our most recent publication in @EuropeanUrology just hit!. Wonderful collaboration with @mishabeltran @sowalsky and Pete Nelson @fredhutch
Tweet media one
0
1
3
@tedradonc
Ted Yanagihara, MD, PhD
2 months
We’ve been running a prospective study of low-dose RT for osteoarthritis, so several people have sent this article to me. Question for people doing this in the US: Are you billing 3D (as this study seems to do)?. What organs need to be spared 50cGy/fx?.
1
3
6
@tedradonc
Ted Yanagihara, MD, PhD
2 months
RT @freddyeescorcia: Great mid-week news on the publication front!. Could it be that our GPC3-selective radiotheranostics agents aimed at #….
0
2
0
@tedradonc
Ted Yanagihara, MD, PhD
2 months
Very useful prospective cohort study with excellent PRO data: Thanks @JCOOP_ASCO for the invitation to discuss palliative radiotherapy for incurable esophageal cancer:
0
4
15
@tedradonc
Ted Yanagihara, MD, PhD
3 months
RT @jryckman3: Fantastic read on The “Linear Non-Thinking Model” this morning!. Excellent take by @free_radical28 🏆🎯. Well worth the brief….
0
3
0
@tedradonc
Ted Yanagihara, MD, PhD
3 months
RT @JAMAOnc: Ablative radiation therapy effectively controlled tumors and provided favorable 2-year survival rates in patients with resecta….
0
29
0
@tedradonc
Ted Yanagihara, MD, PhD
3 months
RT @Katie_Spina: Translational research is a humbling privilege. I am continually inspired by patients who choose to give back by electing….
0
2
0
@tedradonc
Ted Yanagihara, MD, PhD
3 months
RT @nbn426: We are hiring for a talented Radiation Oncology Chair @UTHealthSAMDA - please let me know if I can provide any information abo….
0
6
0
@tedradonc
Ted Yanagihara, MD, PhD
3 months
RT @jryckman3: A fantastic prospective report on H&N #reirradiation from the Tata Memorial group, one of the largest prospective H&N ReRT r….
0
32
0